Table of Contents

~~UNITED~~U.S. ~~STATES~~SECURITIES AND EXCHANGE COMMISSION

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: ~~June 30~~December 31, 2024

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ~~______~~ ________________ to ~~_______~~________________

Commission File ~~No.~~Number: 333-250025

Medicale Corp. (Exact name of registrant as specified in its charter)

(Exact name of registrant as specified in its charter)

Nevada		98-1556944
(State or other jurisdiction of incorporation)		(I.R.S. Employer Identification No.)

Nevada	8000	EIN 98-1556944
(State or other jurisdiction of incorporation or Organization)	(Primary Standard Industrial Classification Code Number)	(IRS Employer Identification Number)

9314 Forest Hill Blvd #929 Wellington, FL 33411

~~9314~~(Address ~~Forest~~of ~~Hill~~principal ~~Blvd~~executive ~~#929~~offices)

Wellington, FL 33411

(407) 245-7339

~~medicalecorp@gmail.com~~(Registrant’s telephone number, including area code)

~~(Address, including zip code, and telephone number,~~__________________________________________________________________

~~including~~Former ~~area code~~name, offormer ~~registrant’s~~address ~~principal~~and former fiscal year, ~~executive~~if ~~offices~~changed since last report)

~~Incorp~~Securities ~~Services,~~registered ~~Inc.~~pursuant to Section 12(b) of the Act: None

~~3773~~Title ~~Howard~~of ~~Hughes~~each ~~Parkway~~class ~~Suite~~Trading ~~500~~Symbol(s) SName of each exchange on which registered N/A N/A N/A

~~Las~~Indicate ~~Vegas~~by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), NVand ~~89169-6014~~(2) has been subject to such filing requirements for the past 90 days: Yes ☒ No ☐

+1 Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (~~702~~§232.405 of this chapter) ~~866-2500~~during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

~~(Name~~Indicate by check mark whether the registrant is a large, ~~address~~accelerated ~~and~~filer, ~~telephone~~an ~~number~~accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of ~~agent~~“large, ~~for~~accelerated filer”, “accelerated filer”, “smaller reporting company” ~~service)~~and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Indicate by checkmark whether the issuer: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one)

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Indicate by ~~checkmark~~check mark whether the registrant is is a shell company (as defined in Rule 12b-2 of the Exchange Act). ~~Yes~~ ☐ No Yes ☒ No

~~Applicable~~APPLICABLE ~~Only~~ONLY toTO ~~Issuer~~ISSUERS ~~Involved~~INVOLVED inIN ~~Bankruptcy Proceedings During the Preceding Five Years. N/A~~BANKRUPTCY

~~Indicate~~PROCEEDINGS byDURING ~~checkmark~~THE ~~whether~~PRECEDING ~~the~~FIVE issuer has filed all documents and reports required to be filed by Section 12, 13 and 15(d) of the Securities Exchange Act of 1934 after the distribution of securities under a plan confirmed by a court. Yes ☐ No ☒YEARS

~~Applicable~~Check ~~Only~~whether the registrant has filed all documents and reports required to ~~Corporate~~be ~~Registrants~~filed by Sections 12, 13 or 15(d) of the Exchange Act after the distribution of securities under a plan confirmed by a court. ☐ YES ☐ NO

~~Indicate~~APPLICABLE ~~the~~ONLY ~~number~~TO ofCORPORATE ~~shares outstanding of each of the issuer’s classes of common stock, as of the most practicable date:~~ISSUERS

Class	Outstanding as of August 14, 2024
Common Stock: $0.0001	5,920,000

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

5,920,000 common shares issued and outstanding as of February 12, 2025.

TABLE OF CONTENTS

PART 1.		FINANCIAL INFORMATION
			Page No.
Item 1.		Financial Statements (Unaudited)	3
PART I - FINANCIAL INFORMATION
	Condensed Balance Sheets as of June 30, 2024 (Unaudited) and September 30, 2023		3
Item 1.	Unaudited Condensed Financial Statements		4
	Condensed Statement of Operations for the three and nine months ended June 30, 2024 and 2023 (Unaudited)		4
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		13
	Condensed Statement of Stockholders’ Equity (Deficit) for the three and nine months ended June 30, 2024 and 2023 (Unaudited)		5
Item 3.	Quantitative and Qualitative Disclosures About Market Risk		16
	Condensed Statement of Cash Flows for the three and nine months ended June 30, 2024 and 2023 (Unaudited)		6
Item 4.	Controls and Procedures		16
	Notes to the Condensed Financial Statements (Unaudited)		7
PART II - OTHER INFORMATION
Item 2.		Management’s Discussion and Analysis of Financial Condition and Results of Operations	12
Item 1.	Legal Proceedings		18
Item 3.		Quantitative and Qualitative Disclosures About Market Risk	14
Item 1A.	Risk Factors		18
Item 4.		Controls and Procedures	14
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds		18
PART II.		OTHER INFORMATION	15
Item 3.	Defaults Upon Senior Securities		18
Item 1.		Legal Proceedings	15
Item 4.	Mine Safety Disclosures		18
Item 2.		Unregistered Sales of Equity Securities and Use of Proceeds	15
Item 5.	Other Information		18
Item 3.		Defaults Upon Senior Securities	15
Item 6.	Exhibits		18
Item 4.		Mine Safety Disclosures	15
SIGNATURES			19
Item 5.		Other Information	15
Item 6.		Exhibits	15
		Signatures	16

~~PART~~CAUTIONARY I.STATEMENT ~~FINANCIAL~~REGARDING ~~INFORMATION~~FORWARD-LOOKING STATEMENTS

~~ITEM~~Except 1for historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). ~~FINANCIAL~~Such ~~STATEMENTS~~forward-looking statements include, among others, those statements including the words “believes”, “anticipates”, “expects”, “intends”, “estimates”, “plans” and words of similar import. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

~~MEDICALE~~Forward-looking ~~CORP~~statements are based on our current expectations and assumptions regarding our business, potential target businesses, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. We caution you therefore that you should not rely on any of these forward-looking statements as statements of historical fact or as guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include changes in local, regional, national, or global political, economic, business, competitive, market (supply and demand) and regulatory conditions.

~~CONDENSED~~A ~~BALANCE~~description ~~SHEETS~~of these and other risks and uncertainties that could affect our business appears in the section captioned “Risk Factors” in our Annual Report on Form 10-K which we filed with the Securities and Exchange Commission (“SEC”) on August 19, 2024 (the “Form 10-K”). The risks and uncertainties described under “Risk Factors” are not exhaustive.

	June 30, 2024			September 30, 2023
		(Unaudited)
ASSETS
Current Assets
Cash	$	159		$	159
Total Current Assets		159			159
Total Assets	$	159		$	159
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current Liabilities
Related party advances	$	–		$	20,480
Accounts payable and accrued expenses		2,135			8,399
Current liabilities from discontinued operations		12,000			12,000
Total Current Liabilities		14,135			40,879
Long term Liabilities
Non-Current Convertible Note Payable		68,076			–
Total Long-term Liabilities		68,076			–
Total Liabilities		82,211			40,879
Stockholders’ Deficit
Common stock, par value $0.0001; 75,000,000 shares authorized, 5,920,000 shares issued and outstanding at June 30, 2024, and September 30, 2023		592			592
Additional paid-in capital		76,320			76,320
Accumulated deficit		(158,964	)		(117,632	)
Total Stockholders’ Deficit		(82,052	)		(40,720	)
Total Liabilities and Stockholders’ Deficit	$	159		$	159

Given these uncertainties, readers of this Quarterly Report on Form 10-Q (“Quarterly Report”) are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future events or developments.

The accompanying notes are an integral part of these condensed financial statements.

~~MEDICALE~~PART ~~CORP.~~I – FINANCIAL INFORMATION

~~CONDENSED~~ITEM ~~STATEMENT~~1. OFFINANCIAL ~~OPERATIONS~~STATEMENTS.

~~(Unaudited)~~MEDICALE CORP.

	Three months ended June 30, 2024			Three months ended June 30, 2023			Nine months ended June 30, 2024			Nine months ended June 30, 2023
General and Administrative Expenses	$	9,288		$	8,537		$	39,198		$	23,366
NET LOSS FROM OPERATIONS		(9,288	)		(8,537	)		(39,198	)		(23,366	)
Other expenses
Interest expense		1,173			–			2,134			–
TOTAL OTHER EXPENSES		1,173			–			2,134			–
Loss before taxes		(10,461	)		(8,537	)		(41,332	)		(23,366	)
Loss from continuing operations		(10,461	)		(8,537	)		(41,332	)		(23,366	)
Income from discontinued operations		–			–			–			455
NET LOSS	$	(10,461	)	$	(8,537	)	$	(41,332	)	$	(22,911	)
NET LOSS PER SHARE: BASIC AND DILUTED
FROM CONTINUING OPERATION	$	(0.00	)	$	(0.00	)	$	(0.01	)	$	(0.00	)
FROM DISCONTINUED OPERATION	$	(0.00	)	$	(0.00	)	$	(0.00	)	$	(0.00	)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING: BASIC AND DILUTED		5,920,000			5,920,000			5,920,000			5,920,000

CONDENSED BALANCE SHEETS

~~The accompanying notes are an integral part of these condensed financial statements.~~(Unaudited)

	December 31,			September 30,
	2024			2024
ASSETS
Current Assets
Cash	$	159		$	159
Total Current Assets		159			159

Total Assets	$	159		$	159

LIABILITIES AND STOCKHOLDERS' DEFICIT
Current Liabilities
Accounts payable	$	995		$	–
Accrued interest payable		5,192			3,507
Current liabilities from discontinued operations		12,000			12,000
Total Current Liabilities		18,187			15,507

Non-current convertible notes payable		93,585			83,585
Total Long-term Liabilities		93,585			83,585

Total Liabilities		111,772			99,092

STOCKHOLDERS' DEFICIT
Common Stock: $0.0001 par value, 75,000,000 shares authorized, 5,920,000 shares issued and outstanding		592			592
Additional paid-in capital		76,320			76,320
Accumulated deficit		(188,525	)		(175,845	)
Total Stockholders' Deficit		(111,613	)		(98,933	)

TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$	159		$	159

~~MEDICALE~~The ~~CORP~~accompanying notes are an integral part of these unaudited condensed financial statements.

~~STATEMENT OF STOCKHOLDERS' DEFICIT~~4

~~For~~MEDICALE ~~the three and nine months ended June 30, 2024 and 2023~~CORP.

~~(Unaudited)~~CONDENSED STATEMENTS OF OPERATIONS

	Common Stock				Additional Paid-in		Accumulated			Total Stockholder’s
	Shares		Amount		Capital		Deficit			Deficit
Balance, September 30, 2022		5,920,000	$	592	$	25,128	$	(80,494	)	$	(54,774	)
Debt forgiveness by related party		–		–		51,192		–			51,192
Net loss for the period ended December 31, 2022		–		–		–		(8,259	)		(8,259	)
Balance, December 31, 2022		5,920,000	$	592	$	76,320	$	(88,753	)	$	(11,841	)
Net loss for the period ended March 31, 2023		–		–		–		(6,115	)		(6,115	)
Balance, March 31, 2023		5,920,000	$	592	$	76,320	$	(94,868	)	$	(17,956	)
Net loss for the period ended June 30, 2023		–		–		–		(8,537	)		(8,537	)
Balance, June 30, 2023		5,920,000	$	592	$	76,320	$	(103,405	)	$	(26,493	)
Balance, September 30, 2023		5,920,000	$	592	$	76,320	$	(117,632	)	$	(40,720	)
Net loss for the period ended December 31, 2023		–		–		–		(19,307	)		(19,307	)
Balance, December 31, 2023		5,920,000	$	592	$	76,320	$	(136,939	)	$	(60,027	)
Net loss for the period ended March 31, 2024		–		–		–		(11,564	)		(11,564	)
Balance, March 31, 2024		5,920,000	$	592	$	76,320	$	(148,503	)	$	(71,591	)
Net loss for the period ended June 30, 2024		–		–		–		(10,461	)		(10,461	)
Balance, June 30, 2024		5,920,000	$	592	$	76,320	$	(158,964	)	$	(82,052	)

(Unaudited)

The accompanying notes are an integral part of these condensed financial statements.


	For the Three Months Ended
	December 31,			December 31,
	2024			2023

Operating Expenses
General and administrative expenses	$	10,995		$	19,307
Total operating expenses		10,995			19,307

Net loss from operations		(10,995	)		(19,307	)

Other expense
Interest expense		1,685			–
Total other expense		(1,685	)		–

Net loss before taxes		(12,680	)		(19,307	)
Provision for income taxes		–			–
Net loss	$	(12,680	)	$	(19,307	)

Net Loss Per Common Share – Basic and Diluted	$	(0.00	)	$	(0.00	)

Weighted Average Common Shares Outstanding		5,920,000			5,920,000

5The accompanying notes are an integral part of these unaudited condensed financial statements.

~~MEDICALE CORP.~~5

~~CONDENSED~~MEDICALE ~~STATEMENT OF CASH FLOWS~~CORP.

~~(Unaudited)~~CONDENSED STATEMENTS OF STOCKHOLDERS’ DEFICIT

	Nine months ended June 30, 2024			Nine months ended June 30, 2023
CASH FLOWS FROM OPERATING ACTIVITIES
Net Loss for the period	$	(41,332	)	$	(23,366	)
Net Loss for the period from discontinued operation		–			455
Changes in assets and liabilities:
Accounts payable and accrued liabilities		(6,264	)		9,412
Related party short term advance		(20,480	)		–
CASH FLOWS USED IN OPERATING ACTIVITIES		(68,076	)		(13,499	)
CASH FLOWS FROM INVESTING ACTIVITIES		–			–
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from Convertible note		68,076			–
Proceeds from related party short term advances		–			13,658
CASH FLOWS PROVIDED BY FINANCING ACTIVITIES		68,076			13,658
Net Cash Increase for Period		–			159
Cash at the beginning of Period		159			–
Cash at end of Period	$	159		$	159
Non-cash investing and financing activities:
Debt forgiveness by related party	$	0		$	51,192

For the three months ended December 30, 2024 and 2023

~~The accompanying notes are an integral part of these condensed financial statements.~~(Unaudited)

6For the three months ended December 31, 2024

MEDICALE CORP.


					Additional					Total
	Common stock				Paid-in		Accumulated			Shareholders'
	Shares		Amount		Capital		Deficit			Deficit

Balance, September 30, 2024		5,920,000	$	592	$	76,320	$	(175,845	)	$	(98,933	)
Net loss		–		–		–		(12,680	)		(12,680	)
Balance, December 31, 2024		5,920,000	$	592	$	76,320	$	(188,525	)	$	(111,613	)

~~Notes~~For to the ~~Condensed~~three ~~Financial~~months ~~Statements~~ended December 31, 2023

June 30, 2024 and 2023

					Additional					Total
	Common stock				Paid-in		Accumulated			Shareholders'
	Shares		Amount		Capital		Deficit			Deficit

Balance, September 30, 2023		5,920,000	$	592	$	76,320	$	(117,632	)	$	(40,720	)
Net loss		–		–		–		(19,307	)		(19,307	)
Balance, December 31, 2023		5,920,000	$	592	$	76,320	$	(136,939	)	$	(60,027	)

~~(Unaudited)~~The accompanying notes are an integral part of these unaudited condensed financial statements.

~~Note 1 – ORGANIZATION AND NATURE OF BUSINESS~~6

MEDICALE CORP ~~(“the Company,”, “we,” “us” or “our”) was incorporated in the State of Nevada on August 17, 2020~~. We plan to offer consulting services and distribution of the dietary supplements. A dietary supplement is a manufactured product intended to supplement the diet when taken by mouth as a pill, capsule, tablet, or liquid. A supplement can provide nutrients either extracted from food sources or synthetic, individually or in combination, in order to increase the quantity of their consumption.

OnCONDENSED ~~December~~STATEMENTS ~~28,~~OF ~~2022,~~CASH the previous majority shareholder of Medicale Corp. (the “Company”) Borisi Alborovi entered into a stock purchase agreement for the sale of 3,200,000 shares of Common Stock of the Company (the “Shares”) to Magenta Acres, Inc.FLOWS

As a result of the acquisition of the Shares, Magenta Acres Inc. holds approximately 54% of the issued and outstanding shares of Common Stock of the Company, and as such it is able to unilaterally control the election of our board of directors, all matters upon which shareholder approval is required and, ultimately, the direction of our Company.(Unaudited)

On December 28, 2022, the previous sole officer and director of the Company, Borisi Alborovi, resigned his positions with the Company. Upon such resignations, Chen Zu De was appointed as Chief Executive Officer, Chairman of the Board, Treasurer and Secretary, and Director of the Company.


	For the Three Months Ended
	December 31,			December 31,
	2024			2023

Cash Flows from Operating Activities:
Net loss	$	(12,680	)	$	(19,307	)
Changes in operating assets and liabilities:
Accounts payable		995			(8,399	)
Accrued interest payable		1,685			–
Net Cash Used in Operating Activities		(10,000	)		(27,706	)

Cash Flows from Financing Activities:
Proceeds from issuance of convertible notes		10,000			27,706
Net Cash Provided by Financing Activities		10,000			27,706

Net Change in Cash and Cash Equivalents		–			–
Cash and Cash Equivalents, beginning of period		159			159
Cash and Cash Equivalents, end of period	$	159		$	159

Supplemental Disclosure Information:
Cash paid for interest	$	–		$	–
Cash paid for taxes	$	–		$	–

AsSee ofaccompanying ~~the date of this report~~notes, ~~the~~which ~~Company~~are ~~had~~an ~~not~~integral ~~yet commenced any~~part ~~operations. All activity through the date~~ of ~~this~~these ~~report~~unaudited ~~relates~~condensed tofinancial ~~preserving cash, attempting to raise capital, and continuing the Company’s public reporting~~statements.

Our principal place of business is located 9314 Forest Hill Blvd #929 Wellington, FL 33411 which is provided to us on a rent free basis by our sole officer and director. Our telephone number is (407) 245-7339.7

~~Note~~MEDICALE ~~2 – GOING CONCERN~~CORP.

~~The~~NOTES ~~accompanying~~TO ~~financial~~THE ~~statements~~UNAUDITED ~~have~~FINANCIAL been prepared in conformity with generally accepted accounting principles in the United States of America (“GAAP”), which contemplate continuation of the Company as a going concern. The Company has an accumulated deficit of $158,964 as of June 30, 2024 and $117,632 as of September 30, 2023. The Company currently has losses and has not completed its efforts to establish a stabilized source of revenues sufficient to cover operating costs over an extended period of time. Therefore, there is substantial doubt about the Company’s ability to continue as a going concern. Management anticipates that the Company will be dependent, for the near future, on additional investment capital to fund operating expenses. The Company intends to position itself so that it will be able to raise additional funds through the capital markets. In light of management’s efforts, there are no assurances that the Company will be successful in this or any of its endeavors or become financially viable and continue as a going concern.STATEMENTS

~~Note~~THREE 3MONTHS –ENDED ~~SUMMARY~~DECEMBER OF31, ~~SIGNIFICANT~~2024 ~~ACCOUNTING~~and ~~POLICIES~~2023

~~Basis~~Note of1 ~~Presentation~~– ORGANIZATION AND NATURE OF BUSINESS

~~The~~MEDICALE ~~accompanying~~CORP ~~unaudited~~(“the ~~condensed~~Company,”, ~~financial~~“we,” ~~statements~~“us” ~~have~~or ~~been~~“our”) ~~prepared~~was incorporated in ~~accordance with~~ the ~~rules~~State ~~and regulations (Regulation S-X)~~ of ~~the~~Nevada ~~Securities~~on ~~and~~August ~~Exchange~~17, ~~Commission (the~~2020. ~~“SEC”)~~We ~~and~~plan ~~with the instructions~~ to ~~Form~~offer ~~10-Q.~~consulting ~~Accordingly,~~services and ~~they~~distribution ~~do not include all~~ of the ~~information~~dietary ~~and~~supplements. ~~footnotes required~~A bydietary ~~generally~~supplement ~~accepted~~is ~~accounting~~a ~~principles~~manufactured ~~for~~product ~~complete~~intended ~~financial~~to ~~statements.~~supplement In the ~~opinion~~diet ~~of management, all adjustments~~when ~~(consisting~~taken ofby ~~normal~~mouth ~~recurring~~as ~~accruals) considered necessary for~~ a ~~fair~~pill, ~~presentation~~capsule, ~~have~~tablet, ~~been~~or ~~included~~liquid. ~~The~~A ~~results~~supplement ofcan ~~operations~~provide nutrients ~~for the~~either ~~three~~extracted ~~and~~from ~~nine~~food ~~months~~sources or ~~ended June 30~~synthetic, ~~2024~~individually ~~are~~or ~~not~~in ~~necessarily indicative of the operating results that may be expected for the year ending September 30~~combination, ~~2024. These unaudited condensed financial statements should be read~~ in ~~conjunction~~order ~~with~~to increase the ~~September~~quantity ~~30,~~of ~~2023,~~their ~~financial statements and notes thereto~~consumption.

7On December 28, 2022, the previous majority shareholder of Medicale Corp. (the “Company”) Borisi Alborovi entered into a stock purchase agreement for the sale of 3,200,000 shares of Common Stock of the Company (the “Shares”) to Magenta Acres, Inc.

~~Use~~As a result of ~~Estimates~~the acquisition of the Shares, Magenta Acres Inc. holds approximately 54% of the issued and outstanding shares of Common Stock of the Company, and as such it is able to unilaterally control the election of our board of directors, all matters upon which shareholder approval is required and, ultimately, the direction of our Company.

~~The~~On ~~preparation~~December of28, ~~financial~~2022, ~~statements~~the inprevious ~~conformity~~sole officer ~~with~~and ~~generally~~director ~~accepted~~of ~~accounting~~the ~~principles~~Company, ~~requires~~Borisi ~~management~~Alborovi, toresigned ~~make~~his ~~estimates~~positions ~~and~~with ~~assumptions that affect~~ the ~~reported~~Company. ~~amounts~~Upon ~~of assets~~such ~~and~~resignations, ~~liabilities~~Chen ~~and~~Zu ~~disclosure~~De ofwas ~~contingent~~appointed as ~~assets~~Chief ~~and~~Executive ~~liabilities~~Officer, atChairman ~~the~~of ~~date~~ the ~~financial~~Board, ~~statements~~Treasurer and ~~the~~Secretary, ~~reported amount of revenues~~ and ~~expenses~~Director ~~during~~of the ~~reporting period~~Company. ~~Actual results could differ from those estimates.~~

~~Deferred~~As ~~Offering~~of ~~Costs~~the date of this report, the Company had not yet commenced any operations. All activity through the date of this report relates to preserving cash, attempting to raise capital, and continuing the Company’s public reporting.

~~Financial~~Our ~~Accounting~~principal ~~Standard~~place ~~Board~~of ~~Accounting Standards~~business ~~Codification~~is ~~number~~located 9314 Forest ~~340-10-S99-1,~~Hill ~~Other~~Blvd ~~Assets~~#929 ~~and Deferred Costs~~Wellington, ~~allows~~FL ~~specific,~~33411 which ~~incremental~~is ~~costs~~provided ~~directly related~~ to ~~securities~~us ~~offerings~~on toa berent ~~deferred~~free ~~and~~basis ~~charged~~by ~~against~~our ~~the~~sole ~~gross~~officer ~~proceed~~and ~~of the offering~~director. ~~The~~Our ~~Company defers applicable syndication~~telephone ~~expenses~~number ~~based~~is on(407) ~~these criteria~~245-7339. ~~The Company will write off all deferred offering costs if a securities offering is aborted.~~

~~Cash~~Note ~~and~~2 ~~Cash~~– GOING ~~Equivalents~~CONCERN

The ~~Company~~accompanying ~~considers~~financial statements have ~~all~~been ~~highly~~prepared ~~liquid~~in ~~investments~~conformity with ~~original~~generally ~~maturities~~accepted accounting principles in the United States of ~~three~~America ~~months~~(“GAAP”), which orcontemplate ~~less~~continuation of the Company as a going concern. The Company has an accumulated deficit of $188,525 and a working capital deficit of 18,028 as of December 31, 2024. The Company currently has losses and has not completed its efforts to establish a stabilized source of revenues sufficient to cover operating costs over an extended period of time. Therefore, there is substantial doubt about the Company’s ability to continue as a going concern. Management anticipates that the Company will be ~~cash~~dependent, ~~equivalents~~for the near future, on additional investment capital to fund operating expenses. The Company intends to position itself so that it will be able to raise additional funds through the capital markets. In light of management’s efforts, there are no assurances that the Company will be successful in this or any of its endeavors or become financially viable and continue as a going concern.

~~Fair Value of Financial Instruments~~8

~~Financial~~Note ~~Accounting~~3 ~~Standards~~– SUMMARY ~~Board~~OF ~~(“FASB”) Accounting~~SIGNIFICANT ~~Standards~~ACCOUNTING Codification (“ASC”) Topic 820 "Fair Value Measurement" defines fair value as the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The standards apply to recurring and nonrecurring fair value measurements of financial and non-financial assets and liabilities. The Company determines the fair values of its assets and liabilities based on a fair value hierarchy that includes three levels of inputs that may be used to measure fair value.POLICIES

~~For~~Basis ~~The~~of ~~three levels are defined as follows:~~presentation

Level 1:	defined as observable inputs such as quoted prices in active markets;
Level 2:	defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and
Level 3:	defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.

The accompanying unaudited condensed financial statements have been prepared in accordance with US GAAP for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three months ended December 31, 2024 are not necessarily indicative of the results that may be expected for the year ending September 30, 2025. Notes to the unaudited interim financial statements that would substantially duplicate the disclosures contained in the audited financial statements for fiscal year 2024 have been omitted. This report should be read in conjunction with the audited financial statements and the footnotes thereto for the fiscal year ended September 30, 2024 included in the Company’s Form 10-K as filed with the Securities and Exchange Commission on January 14, 2025.

~~Due~~Use ~~to its short-term nature, the carrying value~~ of ~~receivables, accounts payable, and advances approximated fair value at June 30, 2024.~~Estimates

~~Revenue~~The ~~Recognition~~preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.

~~The Company follows the guidance of Accounting~~ Standards Codification (ASC) 606, Revenue from Contracts. ASC 606 creates a five-step model that requires entities to exercise judgment when considering the terms of contracts, which includes (1) identifying the contracts or agreements with a customer, (2) identifying our performance obligations in the contract or agreement, (3) determining the transaction price, (4) allocating the transaction price to the separate performance obligations, and (5) recognizing revenue as each performance obligation is satisfied. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the services it transfers to its clients.Reclassifications

~~All~~Certain ~~revenue~~prior ~~generated~~year byamounts have been reclassified to conform to the ~~Company~~current ~~was~~presentation. ~~done so~~These byreclassifications ~~operations~~had ~~that~~no ~~have~~impact ~~been~~on ~~discontinued~~net earnings (loss) or and financial position.

~~Income~~Cash ~~Taxes~~equivalents

~~Income~~The ~~taxes~~Company ~~are~~considers ~~computed~~all ~~using~~highly ~~the~~liquid ~~asset and~~investments ~~liability~~with ~~method.~~maturities ~~Under~~of ~~the~~three ~~asset~~months ~~and~~or ~~liability~~less ~~method,~~at ~~deferred income tax assets and liabilities are determined based on~~ the ~~differences between~~time ~~the financial reporting and tax bases~~ of ~~assets~~purchase ~~and~~to ~~liabilities~~be ~~and~~cash ~~are measured using the currently enacted tax rates and laws~~equivalents. A ~~valuation~~The ~~allowance~~cash isequivalents ~~provided~~as ~~for the amount~~ of ~~deferred~~December ~~tax~~31, ~~assets~~2024 ~~that,~~and 2023 ~~based~~were on$159 ~~available~~and ~~evidence~~$159, ~~are not expected to be realized~~respectively.

8Fair Value of Financial Instruments

~~Long~~FASB ASC Topic 820, "Fair Value Measurement," defines fair value as the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The standards apply to recurring and nonrecurring fair value measurements of financial and non-~~Lived~~financial ~~Assets~~assets –and ~~Intangible~~liabilities. ~~Assets~~The Company determines the fair values of its assets and liabilities based on a fair value hierarchy that includes three levels of inputs that may be used to measure fair value.

WeThe ~~account~~three ~~for~~levels our intangible assets in accordance with ASC Subtopic 350-30, General Intangibles Other Than Goodwill, and ASC Subtopic 360-10-05, Accounting for the Impairment or Disposal of Long-Lived Assets. ASC Subtopic 350-30 requires assets to be measured based on the fair value of the consideration given or the fair value of the assets (or net assets) acquired, whichever is more clearly evident and, thus, more reliably measurable. Further, ASC Subtopic 350-30 requires an intangible asset to be amortized over its useful life and for the useful life to be evaluated every reporting period to determine whether events or circumstances warrant a revision to the remaining period of amortization. If the estimate of useful life is changed the remaining carrying amount of the intangible asset is amortized prospectively over the revised remaining useful life. Costs of internally developing, maintaining, or restoring intangible assets are ~~recognized~~defined as ~~an expense when incurred.~~follows:

Basic Income (Loss) Per Share

Level 1:	defined as observable inputs such as quoted prices in active markets;
Level 2:	defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and
Level 3:	defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.

~~The~~Due ~~Company computes income (loss) per share in accordance with FASB ASC 260 “Earnings per Share.” Basic loss per share is computed by dividing net income (loss) available~~ to ~~common~~its ~~shareholders~~short-term bynature, the ~~weighted~~carrying ~~average number~~ value of ~~outstanding~~cash, ~~common~~director ~~shares~~loans ~~during~~and ~~the~~issuance ~~period.~~of ~~Diluted income (loss) per share gives effect to all dilutive potential~~ common ~~shares~~stock ~~outstanding~~approximated ~~during~~fair ~~the~~value ~~period.~~at ~~Dilutive~~December ~~loss per share excludes all potential common shares if their effect is anti-dilutive. As of June 30~~31, 2024~~, there were no potentially dilutive debt or equity instruments issued or outstanding~~.

~~Recent Accounting Pronouncements~~9

WeBasic ~~have~~Income ~~reviewed~~(Loss) ~~all~~Per ~~the recently issued, but not yet effective, accounting pronouncements and we do not believe any of these pronouncements will have a material impact on the Company.~~Share

~~Note~~The 4Company –computes ~~DISCONTINUED~~income ~~OPERATION~~(loss) per share in accordance with FASB ASC 260 “Earnings per Share”. Basic loss per share is computed by dividing net income (loss) available to common shareholders by the weighted average number of outstanding common shares during the period. Diluted income (loss) per share gives effect to all dilutive potential common shares outstanding during the period. Dilutive loss per share excludes all potential common shares if their effect is anti-dilutive. For the three months ended December 31, 2024 and 2023, convertible notes were potentially dilutive instruments and were not included in the calculation of diluted loss per shares as their effect would be antidilutive.

Through December 31, 2022, the Company’s primary business was the sale of various consumer products and accessories. As of January 1, 2023, the Company ceased operations. On January 9, 2023, a change in control completed as the Company’s former majority shareholder sold his 3,200,000 shares to an investor group. After the change in control, the Company’s operations are determined by the new investor group. As such, the Company accounted for all of its revenue (loss), liabilities and results of operations up to January 1, 2023 as discontinued operations.

Schedule of antidilutive shares
	December 31,		December 31,
	2024		2023
	(Shares)		(Shares)
Convertible notes payable		9,358,500		4,818,600

~~The~~Recent ~~Company~~Accounting ~~has reclassified its previously issued financial statements to segregate the discontinued operations as of the earliest period reported.~~Pronouncements

In August 2020, the FASB issued ASU 2020-06, ASC Subtopic 470-20 “Debt-Debt with Conversion and Other Options” and ASC subtopic 815-40 “Hedging-Contracts in Entity’s Own Equity.” The ~~following~~standard ~~table~~reduced ~~presents~~the ~~information~~number ~~related~~of accounting models for convertible debt instruments and convertible preferred stock. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the ~~liabilities~~host contract, that ~~were~~meet ~~classified~~the definition of a derivative, and that do not qualify for a scope exception from derivative accounting; and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as ~~current~~paid-in ~~liabilities~~capital. ASU 2020-06 removes from ~~discontinued~~U.S. ~~operations~~GAAP the separation models for (1) convertible debt with a CCF and (2) convertible instruments with a beneficial conversion feature (“BCF”). With the adoption of ASU 2020-06, entities will not separately present in ~~our~~equity ~~balance~~an ~~sheets:~~embedded conversion feature these debts. The amendments in this update are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company adopted ASU 2020-06 as of October 1, 2022 and did not record BCF on the issuance of convertible notes with conversion rate below the Company’s market stock price on the date of note issuance.

Schedule of discontinued operations - balance sheet
	June 30, 2024		September 30, 2023
	(Unaudited)
Current Liabilities
Accounts payable and accrued expenses	$	12,000	$	12,000
Total current liabilities from discontinued operations	$	12,000	$	12,000

In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740) - Improvements to Income Tax Disclosures ("ASU 2023-09"), which is intended to enhance the transparency and decision usefulness of income tax disclosures. The amendments in ASU 2023-09 provide for enhanced income tax information primarily through changes to the rate reconciliation and income taxes paid information. ASU 2023-09 is effective for the Company prospectively to all annual periods beginning after December 15, 2024. Early adoption is permitted. We are currently evaluating the impact this update will have on our consolidated financial statements and disclosures.

AsIn ofNovember ~~June~~2023, 30the FASB issued ASU No. 2023-07, ~~2024~~Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures ("ASU 2023-07"), which require public companies disclose significant segment expenses and other segment items on an annual and interim basis and to provide in interim periods all disclosures about a reportable segment's profit or loss and assets that are currently required annually. The guidance is effective for public entities for fiscal years beginning after December 15, 2023, ~~the~~and ~~company~~interim ~~has~~periods ~~not~~within fiscal years beginning ~~generate~~after ~~any~~December ~~revenue~~15, ~~from~~2024. ~~discontinued~~Early ~~operation~~adoption is permitted. The guidance is applied retrospectively to all periods presented in the financial statements, unless it is impracticable. We are currently evaluating the impact this update will have on our consolidated financial statements and disclosures.

9We have evaluated all other recently issued, but not yet effective, accounting pronouncements and do not believe that these accounting pronouncements will have any material impact on our consolidated financial statements or disclosures upon adoption.

~~Note 5 – COMMON STOCK~~10

~~The~~Note ~~Company~~4 ~~has~~– DISCONTINUED ~~75,000,000, $0.0001 par value shares of voting common stock authorized.~~OPERATIONS

~~All~~Through ~~shares~~December of31, ~~common~~2022, ~~stock~~the ~~have voting rights~~Company’s ~~and~~primary ~~are~~business ~~identical.~~was ~~All~~the ~~holders~~sale of ~~shares~~various consumer products and accessories. As of ~~common~~January ~~stock~~1, ~~shall~~2023, atthe ~~every~~Company ~~meeting~~ceased ofoperations. On January 9, 2023, a change in control completed as the ~~stockholders~~Company’s beformer ~~entitled~~majority toshareholder ~~one~~sold ~~vote~~his ~~for~~3,200,000 ~~each~~shares ~~share~~to an investor group. ofAfter the ~~capital~~change ~~stock~~in ~~held~~control, the Company’s operations are determined by the new investor group. As such, ~~stockholder~~the Company accounted for all of its revenue (loss), liabilities and results of operations up to January 1, 2023 as discontinued operations.

OnThe ~~December 28, 2022, Borisi Alborovi, the previous majority shareholder of Medicale Corp. (the “~~Company~~”),~~ ~~entered~~has ~~into~~reclassified aits ~~stock~~previously ~~purchase agreement for~~issued ~~the~~financial ~~sale~~statements ofto ~~3,200,000~~segregate ~~shares~~the ofdiscontinued ~~Common~~operations ~~Stock~~as of the ~~Company~~earliest ~~(the~~period ~~“Shares”) to Magenta Acres, Inc~~reported.

AsThe offollowing ~~June~~table ~~30,~~presents ~~2024~~information related to the ~~company~~liabilities ~~had~~that ~~5,920,000 shares~~were ~~issued~~classified ~~and~~as ~~outstanding.~~current liabilities from discontinued operations in our balance sheets:

Voting Common Stock


	December 31, 2024		September 30, 2024
Current Liabilities
Accounts payable and accrued expenses	$	12,000	$	12,000

Total current liabilities from discontinued operations	$	12,000	$	12,000

~~All~~Through ~~shares~~December of31, ~~common~~2024, ~~stock have voting rights and are identical. All holders of shares of voting common stock shall at every meeting of~~ the ~~stockholders~~Company behas ~~entitled to one vote for~~not ~~each~~generated ~~share~~any ofrevenue ~~the~~from ~~capital~~discontinued ~~stock held by such stockholder~~operation.

~~Non-voting~~Note ~~Common~~5– COMMON ~~Stock~~STOCK

~~All~~The ofCompany ~~the~~has ~~other~~75,000,000, ~~terms of the Non-Voting Common~~$0.0001 par ~~Stock~~value ~~shall~~shares ~~be identical to the Voting Common Stock, except for the right~~ of ~~first~~voting ~~refusal~~common ~~that~~stock ~~attaches to the Non-Voting Common Stock, as explained in the Company’s Bylaws~~authorized.

~~Note~~All 6shares –of ~~INTANGIBLE~~common ~~ASSETS~~stock have voting rights and are identical. All holders of shares of common stock shall at every meeting of the stockholders be entitled to one vote for each share of the capital stock held by such stockholder.

~~The~~As ~~Company purchased and possesses an asset in a form~~ of anDecember ~~operative website~~31, ~~with~~2024 ~~news blog. The Company purchased the website for $12,000~~ and ~~was~~ ~~amortizing the asset straight-line over its five-year useful life or $2,400 per year. Due to the impairment evaluation analysis as of~~ September 30, ~~2022 where we deemed the asset’s carrying amount was not recoverable~~2024, ~~we recognized impairment of $7,200, leaving~~ the ~~Intangible~~company ~~Assets~~had ~~with the Net Book Value of $nil as of June 30~~5,920,000 ~~2024~~shares issued and ~~September 30~~outstanding, ~~2023~~respectively.

~~Note~~Voting 7Common ~~– COMMITMENTS AND CONTINGENCIES~~Stock

InAll ~~the~~shares ~~normal course~~ of ~~business,~~common ~~the~~stock ~~Company~~have ~~may~~voting ~~become~~rights and aare ~~party~~identical. ~~to litigation~~All ~~matters~~holders ~~involving~~of ~~claims~~shares ~~against~~of ~~it.~~voting Atcommon ~~June~~stock ~~30,~~shall ~~2024,~~at ~~there~~every ~~are~~meeting noof ~~current~~the ~~matters~~stockholders ~~that~~be ~~would~~entitled ~~have~~to aone ~~material~~vote ~~effect~~for each onshare of the ~~Company’s~~ ~~financial~~capital ~~position~~stock orheld ~~results~~by ofsuch ~~operations~~stockholder.

~~Note~~Non-voting 8Common ~~– RELATED PARTY TRANSACTIONS~~Stock

~~The~~All ~~sole~~of ~~officer~~the ~~and~~other ~~director,~~terms ~~Borisi~~of ~~Alborovi, was~~ the ~~only~~Non-Voting ~~related~~Common Stock ~~party~~shall ~~with~~be ~~whom~~identical to the ~~Company~~Voting ~~had~~Common ~~transactions~~Stock, ~~with~~except ~~during~~for the ~~period~~right ~~from~~of ~~inception~~first onrefusal ~~August~~that ~~17,~~attaches ~~2020~~to ~~through~~the ~~December 31~~Non-Voting Common Stock, as ~~2022~~explained in the Company’s Bylaws.

On December 28, 2022, the previous sole officer and director, Borisi Alborovi, resigned his positions with the Company. Upon such resignations, Chen Zu De was appointed as Chief Executive Officer, Chairman of the Board, Treasurer and Secretary, and Director of the Company.11

AsNote a6– CONVERTIBLE ~~result~~NOTE of the acquisition of the Shares on December 28, 2022, the previous majority shareholder of Medicale Corp. (the “Company”) Borisi Alborovi forgive the debt that due to him, with the amount of $51,192.PAYABLE

As of December 31, 2023 and September 30, 2023, the Company owed Mr. Alborovi $nil and $nil respectively, for operating expenses on behalf of the Company. The amounts due to the related party are unsecured and non-interest bearing with no set terms of repayment.

Schedule of convertible notes payable	December 31,		September 30,
	2024		2024
December 2023	$	48,186	$	48,186
March 2024		10,602		10,602
June 2024		9,288		9,288
September 2024		15,509		15,509
December 2024		10,000		–
	$	93,585	$	83,585

AsOn ofDecember ~~June~~31, 302023, ~~2024~~the ~~and~~Company ~~September~~entered into ~~30,~~a ~~2023,~~Convertible ~~the Company~~Note ~~owed~~agreement ~~Chen~~with Zua Dethird ~~$nil~~party ~~and~~at $~~nil respectively~~48, 186 for paying operating expenses on behalf of the Company. The ~~amounts~~note ~~due~~bears toa ~~the~~8% ~~related~~interest ~~party are~~rate ~~unsecured~~per year and ~~non-interest~~matures on ~~bearing~~December ~~with~~31, no2029. ~~set~~The ~~terms~~note ofcan ~~repayment~~be converted to the Company’s common stock at $0.01 per share. As of December 31, 2024, the accrued interest is $3,865.

On March 31, 2024, the Company entered into a Convertible Note agreement with a third party at $10,602 for paying operating expenses on behalf of the Company. The note bears a 8% interest rate per year and matures on March 31, 2030. The note can be converted to the Company’s common stock at $0.01 per share. As of December 31, 2024, the accrued interest is $639.

On June 30, 2024, the Company entered into a Convertible Note agreement with a third party at $9,288 for –paying ~~CONVERTIBLE~~operating ~~NOTE~~expenses ~~PAYABLE~~on behalf of the Company. The note bears a 8% interest rate per year and matures on March 31, 2030. The note can be converted to the Company’s common stock at $0.01 per share. As of December 31, 2024, the accrued interest is $375.

On ~~December~~September 3130, ~~2023~~2024, the ~~company~~Company entered into a Convertible Note agreement with a third party at $2115,~~051~~509 for paying operating expenses on behalf of the Company. The note bears a 8% interest rate per year and matures on ~~December~~March 31, ~~2029~~2030. The note can be converted to the Company’s common stock at $0.01 per share. As of ~~June~~December 3031, 2024, the accrued interest is $~~1,923~~313.

On ~~March~~December 31, 2024, the ~~company~~Company entered into a Convertible Note agreement with a third party at $10,~~602~~000 for paying operating expenses on behalf of the Company. The note bears a 8% interest rate per year and matures on March 31, 2030. The note can be converted to the Company’s common stock at $0.01 per share. As of ~~June~~December 3031, 2024, the accrued interest is $~~211~~nil.

OnDuring ~~June 30, 2024,~~ the ~~company~~three ~~entered~~months ~~into~~ended aDecember ~~Convertible~~31, ~~Note agreement~~2024 ~~with~~and a2023, ~~third~~the ~~party~~Company atincurred $91,~~288.~~685 ~~The~~and $nil note ~~bears a 8%~~ interest ~~rate~~expense. ~~per~~As ~~year~~of ~~and~~December ~~matures on March~~ 31, ~~2030.~~2024 ~~The~~and ~~note~~September ~~can be converted to the Company’s common stock at $0.01 per share. As of June~~ 30, 2024, ~~the~~ accrued interest payable iswas $~~nil~~5,192 and $3,507, respectively.

Note 10 7– SUBSEQUENT EVENTS

In accordance with SFAS 165 (ASC 855-10) the Company has analyzed its operations subsequent to ~~June~~December 3031, 2024 to the date these financial statements were issued and has determined that it does not have any material subsequent events to disclose in these financial statements.

1112

ITEM 2. MANAGEMENT'’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF ~~OPERATION~~OPERATIONS.

~~FORWARD~~Forward-Looking ~~LOOKING STATEMENTS~~Statements

~~Statements~~This ~~made~~quarterly inreport ~~this~~contains ~~Form 10-Q that are not historical or current facts are "~~forward-looking statements". ~~made~~These ~~pursuant~~statements relate to ~~the~~future ~~safe~~events ~~harbor~~or ~~provisions~~our offuture ~~Section~~financial ~~27A of the Securities Act of 1933 (the "Act") and Section 21E of the Securities Exchange Act of 1934~~performance. ~~These~~In ~~statements~~some ~~often~~cases, you can beidentify ~~identified~~forward-looking statements by ~~the~~terminology ~~use of terms~~ such as "“may,"” ~~"will~~“should,"” ~~"expect~~“expects,"” ~~"believe~~“plans,"” ~~"anticipate~~“anticipates,"” “believes,” ~~"estimate~~“estimates,~~" "approximate"~~” “predicts,” “potential” or "“continue,"” or the negative of ~~thereof.~~these Weterms ~~intend~~or ~~that~~other ~~such~~comparable ~~forward-looking~~terminology. These statements beare ~~subject~~only ~~to the~~predictions ~~safe~~and ~~harbors~~involve ~~for~~known ~~such~~and ~~statements.~~unknown Werisks, ~~wish~~uncertainties and toother ~~caution~~factors ~~readers~~that ~~not~~may tocause ~~place~~our ~~undue~~or ~~reliance~~our onindustry’s ~~any~~actual ~~such~~results, ~~forward-looking~~levels ~~statements~~of activity, ~~which speak~~performance, ~~only~~or asachievements ofto ~~the~~be ~~date~~materially different ~~made.~~from ~~Any~~any ~~forward-looking~~future ~~statements~~results, ~~represent~~levels ~~management's~~of ~~best~~activity, ~~judgment~~performance asor toachievements ~~what~~expressed ~~may~~or ~~occur~~implied inby ~~the~~these ~~future. However,~~ forward-looking statements. Although ~~are~~we ~~subject~~believe tothat ~~risks,~~the ~~uncertainties~~expectations ~~and~~reflected ~~important~~in ~~factors~~the ~~beyond~~forward-looking ~~our~~statements ~~control~~are ~~that~~reasonable, ~~could~~we ~~cause~~cannot ~~actual~~ guarantee future results, levels ~~and~~of ~~events~~activity, toperformance, ~~differ~~or ~~materially~~achievements. ~~from~~Except ~~historical~~as ~~results~~required ofby ~~operations~~applicable ~~and~~law, ~~events~~including ~~and~~the ~~those~~securities ~~presently~~laws ~~anticipated~~of orthe ~~projected.~~United States, Wewe ~~disclaim~~do ~~any~~not ~~obligation~~intend ~~subsequently~~ to ~~revise~~update any of the forward-looking statements to ~~reflect~~conform ~~events~~these orstatements ~~circumstances after the date of such statement or~~ to ~~reflect~~actual ~~the occurrence of anticipated or unanticipated events~~results.

~~Employees~~Our unaudited financial statements are stated in United States Dollars (US$) and ~~Employment~~are ~~Agreements~~prepared in accordance with United States Generally Accepted Accounting Principles. The following discussion should be read in conjunction with our financial statements and the related notes that appear elsewhere in this quarterly report. The following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed below and elsewhere in this quarterly report.

AtIn ~~present,~~this wequarterly ~~have no employees other than our officer and director. We presently do not have pension~~report, ~~health,~~unless ~~annuity,~~otherwise ~~insurance~~specified, ~~stock options, profit sharing or similar benefit plans;~~ ~~however,~~all wedollar ~~may~~amounts ~~adopt~~are ~~such~~expressed ~~plans~~ in ~~the~~United ~~future.~~States ~~There~~dollars ~~are~~and ~~presently~~all noreferences ~~personal~~to ~~benefits~~“common ~~available~~shares” refer to ~~any~~the ~~officers,~~common ~~directors~~shares in orour ~~employees~~capital stock.

~~Results~~As ofused ~~Operation~~in this quarterly report, the terms “we, “us,” “our” and “our company” mean Medicale Corp., unless otherwise indicated.

~~Our~~General financial statements have been prepared assuming that we will continue as a going concern and, accordingly, do not include adjustments relating to the recoverability and realization of assets and classification of liabilities that might be necessary should we be unable to continue in operation.Overview

WeMedicale ~~expect~~Corp (“we,” ~~will~~“our” or ~~require~~the ~~additional~~“Company”) ~~capital~~was incorporated in the State of Nevada on August 17, 2020. To date we have not generated revenue from our business operations. Furthermore, as we are still in the early stages of developing our business and expect to operate at a loss as we ~~meet~~grow our ~~long~~business. ~~term~~There ~~operating~~is ~~requirements~~little historical financial information about our Company upon which to base an evaluation of our performance or to make a decision regarding an investment in our shares. We ~~expect~~cannot toguarantee ~~raise~~that ~~additional~~we ~~capital~~will ~~through~~be successful in our business operations or that we will achieve significant, ~~among~~if ~~other~~any, ~~things~~level of market acceptance for our proposed business operations and products. Our business could be subject to any or all of the problems, expenses, delays and risks inherent in the ~~sale~~establishment of ~~equity~~a ornew ~~debt~~business enterprise, ~~securities~~including limited capital resources, possible changes in consumer interest, possible cost overruns due to price and cost increases in services or products we require.

~~Three~~We ~~Months~~have ~~Ended~~never ~~June~~been 30subject to any bankruptcy proceedings. The principal place of business is now located at 9314 Forest Hill Blvd #929, ~~2024~~Wellington, ~~and~~FL ~~2023:~~33411. Our telephone number is (407)245-7339.

~~During~~As of the ~~three~~date ~~months~~of ~~ended~~this ~~June 30~~report, ~~2024~~the ~~and~~Company had not yet commenced any ~~2023~~operations. All activity through the ~~Company’s~~date ~~net~~of ~~income~~this ~~from~~report ~~discontinued~~relates ~~operations~~to ~~were~~preserving ~~$nil~~cash, attempting to raise capital, and continuing the Company’s public reporting.

~~Our net loss for the three months ended June 30, 2024 was $10,461. Operating expenses consist of mainly professional fees and interest fee.~~13

~~Our~~Results ~~net loss for the three months ended June 30, 2023 was $8,537. Operating expenses consist~~ of ~~mainly professional fees.~~Operations

~~Nine~~The ~~Months~~following ~~Ended~~summary ~~June~~of 30our results of operations should be read in conjunction with our financial statements for the three months ended December 31, 2024 and 2023: which are included herein.

~~During~~Three ~~the nine~~ months ended ~~June~~December 3031, 2024 ~~and~~compared ~~2023~~to ~~the~~three ~~Company’s~~months ~~net~~ended ~~income~~December ~~from~~31, ~~discontinued operations were $nil and $455.~~2023

Our net loss for the nine months ended June 30, 2024 was $41,332. Operating expenses consist of mainly professional fees.

	Three Months Ended
	December 31,
	2024		2023		Changes			%

Operating expenses	$	10,995	$	19,307		(8,312	)		(43%	)
Other expenses		1,685		–		1,685			100%
Net Loss	$	12,680	$	19,307	$	(6,627	)		(34%	)

Our net loss for the ~~nine~~three months ended ~~June 30,~~December ~~2023~~31, 2024 was $2212,~~911.~~680 ~~Operating~~compared ~~expenses~~with ~~consist~~net loss of ~~mainly~~$19,307 ~~professional~~for the three months ended December 31, 2023 due to the decrease in audit and review fees, transfer agent fees and filing fees.

12Liquidity and Capital

~~Liquidity~~Working ~~and~~ Capital ~~Resources~~

As of June 30, 2024, our total assets were $159 consisting of cash of $159. As of June 30, 2024, our current liabilities were $2,135, and current liabilities from discontinued operations of $12,000.

	As of			As of
	December 31,			September 30,
	2024			2024			Changes		%

Current Assets	$	159		$	159		$	–		–
Current Liabilities	$	18,187		$	15,507		$	2,680		17%
Working Capital Deficiency	$	(18,028	)	$	(15,348	)	$	2,680		(17%	)

~~Cash~~As ~~Flows~~at ~~from~~December ~~Operating~~31, ~~Activities~~2024 and September 30, 2024, our company had cash of $159.

WeAs ~~have~~at ~~not~~December ~~generated~~31, ~~positive~~2024, ~~cash~~our ~~flows~~Company ~~from~~had current ~~operating~~liabilities ~~activities.~~of ~~For~~$18,187 ~~the~~as ~~nine~~compared ~~months~~to ~~ended~~$15,507 ~~June~~as of September 30, 2024. ~~and~~The ~~2023,~~increase ~~net~~in ~~cash~~current ~~flows~~liabilities ~~used~~was indue ~~operating~~to ~~activities~~the ~~were~~increase ~~$68,076~~in accrued interest payable and ~~$13,499, respectively~~accounts payable.

~~Cash~~As ~~Flows~~at ~~from~~December ~~Investing~~31, ~~Activities~~2024, our Company had a working capital deficiency of $18,028 compared with a working capital deficit of $15,348 as at September 30, 2024. The increase in working capital deficit was primarily due to the increase in accrued interest payable and accounts payable.

~~We have not generated cash flows from investing activities during the nine months ended March 31, 2024 and 2023, respectively.~~14

Cash Flows ~~from Financing Activities~~

We have generated cash flows from financing activities in the amount $68,076 and $13,658 during the nine months ended June 30, 2024 and 2023, respectively.

	Three Months Ended
	December 31,
	2024			2023			Changes			%

Cash flows used in operating activities	$	(10,000	)	$	(27,706	)	$	17,706			(64%	)
Cash flows provided by financing activities		10,000			27,706			(17,706	)		(64%	)
Net changes in cash	$	–		$	–		$	–			–

~~Plan~~Cash ofFlow ~~Operation~~from ~~and~~Operating ~~Funding~~Activities

We ~~expect~~have ~~that~~not ~~working~~generated ~~capital~~positive ~~requirements~~cash ~~will~~flow from ~~continue~~operating toactivities. beDuring ~~funded~~the ~~through~~three amonths ~~combination~~ended ofDecember ~~our~~31, ~~existing~~2024, ~~funds~~net ~~and~~cash ~~further~~used ~~issuances~~in ofoperating ~~securities.~~activities ~~Our~~was ~~working~~$10,000 ~~capital~~compared ~~requirements are expected~~ to ~~increase~~$27,706 used induring ~~line~~the ~~with~~three ~~the~~months ~~growth~~ended ofDecember ~~our~~31, ~~business~~2023.

~~Existing~~Cash ~~working~~flows ~~capital,~~used ~~further~~in ~~advances~~operating ~~and debt~~activities ~~instruments, and anticipated cash flow are expected to be adequate to fund our operations over~~ during the ~~next~~ three months. Weended ~~have~~December ~~no lines of credit or other bank financing arrangements. Generally~~31, ~~we have financed operations to date through the proceeds of the private placement of equity and debt instruments. In connection with our business plan~~2024, ~~management~~comprised ~~anticipates additional increases in operating expenses and capital expenditures relating to: (i) acquisition~~ of ~~inventory; (ii) developmental expenses associated with~~ a ~~start-up~~net ~~business; and~~loss ~~(iii) marketing expenses. We intend to finance these expenses with further issuances~~ of ~~securities~~$12, ~~and debt issuances. Thereafter~~680, we ~~expect~~reduced weby will need to raise additional capital and generate revenues to meet long-term operating requirements. Additional issuances of equity or convertible debt securities will result in dilution to our current shareholders. Further, such securities might have rights, preferences or privileges senior to our common stock. Additional financing may not be available upon acceptable terms, or at all. If adequate funds are not available or are not available on acceptable terms, we may not be able to take advantage of prospective new business endeavors or opportunities, which could significantly and materially restrict our business operations. We will have to raise additional funds in the next twelve months in order to sustain and expand our operations. We currently do not have a ~~specific~~net ~~plan~~change ~~of how we will obtain such funding; however, we anticipate that additional funding will be~~ in ~~the~~operating ~~form~~liabilities of ~~equity financing from the sale of our common stock. We have and will continue to seek to obtain short-term loans from our directors~~$2, ~~although no future arrangement for additional loans has been made~~680. ~~We do not have any agreements with our directors concerning these loans. We do not have any arrangements in place for any future equity financing.~~

13Cash flows used in operating activities during the three months ended December 31, 2023, comprised of a net loss of $19,307, increased by a net change in operating liabilities of $8,399.

~~Off-Balance~~Cash ~~Sheet~~Flow ~~Arrangements~~from Investing Activities

AsDuring of the ~~date~~three ofmonths ~~this~~ended ~~Quarterly~~December ~~Report~~31, ~~we do~~2024 ~~not~~and ~~have~~2023, ~~any~~our ~~off-balance~~Company ~~sheet~~did ~~arrangements~~not ~~that~~ have orany ~~are~~investing reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investorsactivities.

~~Going~~Cash ~~Concern~~Flow from Financing Activities

~~The~~During ~~financial~~the ~~statements~~three ~~have~~months ~~been~~ended ~~prepared~~December ~~"assuming~~31, 2024 ~~that~~and we2023, ~~will~~net ~~continue~~cash asprovided aby ~~going~~financing ~~concern,"~~activities ~~which~~was ~~contemplates~~$10,000 ~~that~~and we$27,706 ~~will~~for ~~realize~~proceed ~~our~~from ~~assets~~the ~~and~~issuance ~~satisfy~~of ~~our~~convertible ~~liabilities~~notes ~~and~~to ~~commitments~~non-affiliates infor ~~the~~paying ~~ordinary~~operating ~~course~~expenses, ~~of business~~respectively.

~~ITEM~~Going ~~3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK~~Concern

NoAs ~~report~~of December 31, 2024, we had an accumulated deficit of $188,525. We believe that its existing capital resources may not be adequate to enable it to continue as a going concern. Management anticipates that the Company will be dependent, for the near future, on additional investment capital to fund operating expenses. The Company intends to position itself so that it will be able to raise additional funds through the capital markets. The accompanying condensed financial statements do not include any adjustments that might be necessary should we be unable to continue as a going concern. If we fail to generate positive cash flow or obtain additional financing, when required, we may have to modify, delay, or abandon some or all of our future business plans.

~~ITEM~~Off-Balance 4.Sheet ~~CONTROLS AND PROCEDURES~~Arrangements

~~Our~~We ~~management~~have isno ~~responsible for establishing and maintaining a system of disclosure controls and procedures (as defined in Rule 13a~~off-~~15(e)~~balance ~~and~~sheet ~~15d-15(e)~~arrangements ~~under the Exchange Act)~~ that ishave ~~designed~~or toare ~~ensure~~reasonably ~~that~~likely ~~information required~~ to behave ~~disclosed~~a bycurrent ~~us in the reports that we file~~ or ~~submit~~future ~~under~~effect ~~the~~on ~~Exchange~~our ~~Act~~financial ~~is recorded~~condition, ~~processed,~~changes ~~summarized and reported, within the time periods specified~~ in ~~the~~financial ~~Commission’s rules and forms. Disclosure controls and procedures include~~condition, ~~without limitation, controls and procedures designed to ensure that information required to be disclosed~~revenues ~~by an issuer in the reports that it files~~ or ~~submits~~expenses, ~~under~~results ~~the~~of ~~Exchange~~operations, ~~Act is accumulated and communicated to the issuer’s management~~liquidity, ~~including~~ ~~its~~capital ~~principal~~expenditures ~~executive officer~~ or ~~officers~~capital ~~and~~resources ~~principal~~that ~~financial~~are ~~officer~~material ~~or officers, or persons performing similar functions, as appropriate~~ to ~~allow timely decisions regarding required disclosure~~stockholders.

An evaluation was conducted under the supervision and with the participation of our management of the effectiveness of the design and operation of our disclosure controls and procedures as of June 30, 2024. Based on that evaluation, our management concluded that our disclosure controls and procedures were not effective as of such date to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms. Such officer also confirmed that there was no change in our internal control over financial reporting during the three and nine months period ended June 30, 2024 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.15

14Critical Accounting Policies

~~PART~~The IIpreparation of financial statements in accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. ~~OTHER~~A ~~INFORMATION~~change in managements’ estimates or assumptions could have a material impact on our financial condition and results of operations during the period in which such changes occurred. Actual results could differ from those estimates. Our financial statements reflect all adjustments that management believes are necessary for the fair presentation of their financial condition and results of operations for the periods presented.

~~ITEM~~Recent 1.Accounting ~~LEGAL PROCEEDINGS~~Pronouncements

Management ishas ~~not~~considered ~~aware~~all ofrecent ~~any legal proceedings~~accounting ~~contemplated~~pronouncements ~~by any governmental authority or any other party involving us or our properties~~issued. AsOur ofcompany’s ~~the~~management ~~date~~believes ofthat ~~this~~these ~~Quarterly~~recent ~~Report, no~~pronouncements ~~director,~~will ~~officer or affiliate is (i) a party adverse to us in any legal proceeding, or (ii) has an adverse interest to us in any legal proceedings. Management is~~ not ~~aware of any other legal proceedings pending or that~~ have ~~been~~a ~~threatened~~material ~~against~~effect uson or our financial ~~properties~~statements.

ITEM 23. ~~UNREGISTERED~~QUANTITATIVE ~~SALES~~AND OFQUALITATIVE ~~EQUITY~~DISCLOSURES ~~SECURITIES AND~~ABOUT ~~USE~~MARKET ~~OF PROCEEDS~~RISK.

NoAs ~~report~~a “smaller reporting company,” we are not required to provide the information required by this Item.

ITEM 34. ~~DEFAULTS~~CONTROLS ~~UPON~~AND ~~SENIOR SECURITIES~~PROCEDURES.

NoEvaluation ~~report~~of ~~required.~~Disclosure Controls and Procedures

~~ITEM~~Disclosure 4controls and procedures are controls and procedures that are designed to ensure that information required to be disclosed in our reports filed under the Exchange Act is recorded, processed, summarized, and reported, within the time periods specified in the SEC’s rules. ~~MINE~~Disclosure ~~SAFETY~~controls ~~DISCLOSURES~~and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by our company in the reports that it files or submits under the Exchange Act is accumulated and communicated to our management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our management carried out an evaluation under the supervision and with the participation of our Principal Executive Officer and Principal Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rules 13a-15(e) and 15d-15(e) under the Exchange Act, as of December 31, 2024. Based upon that evaluation, our Principal Executive Officer and Principal Financial Officer have concluded that our disclosure controls and procedures were not effective as of December 31, 2024.

~~Not~~Our ~~applicable.~~disclosure controls and procedures are not effective for the following reasons:

~~ITEM~~We 5did not maintain effective controls to identify and maintain segregation of duties in identifying, authorizing, approving, accounting for, and disclosing significant estimates, related-party transactions, significant unusual transactions, and other non-routine events and transactions. ~~OTHER~~Specifically, ~~INFORMATION~~we only have one individual, our sole officer and director, who reviews, evaluates, approves, and records transactions and initiates journal entries, approves journal entries, and posts journal entries to the general ledger. There is no independent review of any financial duties performed by this individual.

During the quarter ended June 30, 2024, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.16

~~ITEM~~Changes 6.in ~~EXHIBITS~~Internal Control Over Financial Reporting

31	Certification of the Chief Executive Officer and the Chief Financial Officer pursuant to Section 302 of Sarbanes-Oxley Act of 2002
32	Certification of the Chief Executive Officer and the Financial Officer pursuant to Section 302 of Sarbanes-Oxley Act of 2002
101.INS	Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)
101.SCH	Inline XBRL Taxonomy Extension Schema Document
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document
104	Cover Page Interactive Data File (formatted in IXBRL, and included in exhibit 101)

During the period covered by this report there were no changes in our internal control over financial reporting that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

15Limitations on the Effectiveness of Internal Controls

~~SIGNATURES~~Our management do not expect that our disclosure controls and procedures or our internal control over financial reporting are or will be capable of preventing or detecting all errors or all fraud. Any control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements, due to error or fraud will not occur or that all control issues and instances of fraud, if any, within the company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns may occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are subject to risk.

Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized in 9314 Forest Hill Blvd #929, Wellington, FL 33411.17

~~MEDICALE~~PART ~~CORP.~~II ~~By:~~– ~~/s/~~OTHER ~~J. Chen Zu De President, Treasurer, Secretary and Director (Principal Executive, Financial and Accounting Officer)~~INFORMATION

InITEM ~~accordance~~1. ~~with~~LEGAL ~~the requirements of the Securities Act of 1933, this registration statement was signed by the following persons in the capacities and on the dates stated~~PROCEEDINGS.

Signature	Title	Date
/s J. Chen Zu De
Chen Zu De	President, Treasurer, Secretary and Director (Principal Executive, Financial and Accounting Officer)	August 15, 2024

We know of no material, existing or pending legal proceedings against us, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to our company.

16ITEM 1A. RISK FACTORS.

As a “smaller reporting company,” we are not required to provide the information required by this Item.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

None

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

None

ITEM 4. MINE SAFETY DISCLOSURES.

Not applicable.

ITEM 5. OTHER INFORMATION.

	(a)	None.

	(b)	None.

	(c)	Rule 10b5-1 Trading Plans. During the three months ended December 31, 2024, no director or Section 16 officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.

ITEM 6. EXHIBITS

Exhibit No.		Description
31.1		Certification of Principal Executive Officer and Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1		Certification of Principal Executive Officer and Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS		XBRL Instance Document
101.SCH		XBRL Schema Document
101.CAL		XBRL Calculation Linkbase Document
101.DEF		XBRL Definition Linkbase Document
101.LAB		XBRL Label Linkbase Document
101.PRE		XBRL Presentation Linkbase Document

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	Medicale Corp.

Date: February 18, 2025	By:	/s/ Chen Zu De
		Chen Zu De
		Chief Executive Officer and
		Chief Financial Officer

Filing Compare · Medicale Corp.